InstalabLoading...
InstalabLoading...
Candida albicans lives quietly on the skin, in the gut, and in the mouth of most healthy adults. Your immune system keeps it in check, and in the process, it produces antibodies against it. This test measures one of those antibodies, IgG (immunoglobulin G), the type your body makes for long-term immune memory. A positive result means your immune system has noticed Candida and built a response. The question is whether that response reflects harmless coexistence or something worth investigating.
This is not a test that gives you a simple "healthy" or "unhealthy" number. Most adults carry detectable Candida IgG because most adults have been exposed to this yeast at some point. The value lies in what an unusually high level, or a rising trend, might signal about gut health, immune burden, or, in specific clinical settings, a deeper fungal infection. Understanding what this antibody can and cannot tell you is the key to using it well.
IgG antibodies are proteins made by a type of white blood cell called a B cell. When your immune system encounters a foreign organism like Candida albicans, it creates IgG antibodies that recognize specific parts of that organism. These antibodies persist in your blood for months to years, serving as a record of past encounters. A higher level generally means more exposure, a stronger immune reaction, or both.
The test does not measure Candida itself. It measures your immune system's reaction to Candida. This is an essential distinction. You can have high antibodies from past exposure even if no active overgrowth exists right now. Conversely, someone whose immune system is severely weakened may have low antibodies despite an active, serious infection, because their immune system cannot mount a proper response.
In a study using a sensitive lab method called a radioimmunoassay, all healthy blood donors had detectable anti-Candida IgG, with levels typically ranging from about 5 to 45 micrograms per milliliter. Hospitalized adults showed a wider range, with some reaching 100 to 300 micrograms per milliliter, overlapping significantly with levels seen in people with confirmed Candida infections. This overlap is the central challenge of interpreting the test.
The setting where Candida IgG testing has been studied most is the intensive care unit (ICU), where doctors need to distinguish between patients who simply carry Candida on their skin or in their gut (colonization) and those with a dangerous bloodstream or deep-tissue infection (invasive candidiasis). In critically ill patients, especially those recovering from abdominal surgery, Candida IgG tests can help make that distinction.
One well-studied version of this test, the Candida albicans germ-tube antibody test (known as CAGTA), measures IgG directed at a specific structure Candida forms when it shifts from a harmless yeast shape into an invasive thread-like form. CAGTA is a specialized assay, not identical to the general Candida IgG test offered by most commercial labs. In ICU studies, CAGTA detected invasive candidiasis with a sensitivity of about 84% (it caught roughly 84 out of 100 true cases) and a specificity of about 95% (it correctly cleared roughly 95 out of 100 people who did not have the infection). Prior surgery was the strongest factor associated with a positive result.
When specialized research assays target specific Candida proteins, accuracy improves further. IgG against two enzymes the fungus produces, called enolase and fructose-bisphosphate aldolase, achieved a combined sensitivity of about 90% and specificity of about 91% for diagnosing bloodstream Candida infection in a study of 475 hospital patients. The combination also had a negative predictive value of 97%, meaning a negative result was very reliable for ruling out the infection. These performance figures come from targeted research assays and may not reflect the accuracy of the general Candida IgG test available through standard commercial labs.
Outside the ICU, elevated Candida IgG has turned up in several other conditions, though the findings are associational rather than proof that Candida caused the problem.
People with Crohn's disease showed elevated antibodies to both Candida albicans and baker's yeast (Saccharomyces cerevisiae) in a study of 45 participants, suggesting that immune reactions to gut fungi may play a role in inflammatory bowel disease. A separate line of research found that Candida albicans produces a surface protein that structurally resembles gluten, and that antibodies against this protein overlap with antibodies found in celiac disease. In a study of 226 individuals, this cross-reactivity between Candida and gluten proteins was confirmed, reinforcing a potential link between fungal exposure and celiac disease in genetically susceptible people.
In a study of 947 people, elevated Candida IgG was more common in women with schizophrenia and bipolar disorder than in controls, and it was associated with lower scores on memory tests in those groups. The connection was sex-specific: it appeared primarily in women, not men. Separately, children with autism spectrum disorder showed higher rates of positive Candida IgG compared to typically developing children in a study of 80 participants. These associations do not prove that Candida causes psychiatric or neurodevelopmental symptoms, but they suggest that immune responses to this fungus may be more relevant to brain health than previously thought.
In patients with severe COVID-19, elevated Candida albicans IgG was a marker of gut fungal overgrowth and prolonged activation of neutrophils (a type of white blood cell that fights infections). This finding, from research published in Nature Immunology, suggests that Candida in the gut can fuel a broader inflammatory response during serious illness, and that IgG levels may reflect the degree of that fungal burden.
This is a Tier 3 marker for preventive use, meaning there are no standardized clinical cutpoints that apply to a healthy person ordering this test on their own. The thresholds that exist were developed for specific hospital populations and specific assay formats, and they do not translate directly to wellness screening.
Most commercial labs report Candida albicans IgG as an index value with qualitative categories: negative, equivocal, or positive. The exact cutpoint depends on the specific assay your lab uses. A "positive" result in a healthy person most likely reflects normal immune exposure to a common fungus, not an active infection. What matters more than a single result is the context: your symptoms (if any), your overall immune health, and whether the level is changing over time.
| Result Category | What It Typically Means |
|---|---|
| Negative | Low or undetectable IgG response to Candida. Either minimal past exposure or, rarely, an immune system unable to produce antibodies. |
| Equivocal | Borderline result. Worth retesting in 4 to 6 weeks to see if levels are rising or stable. |
| Positive | Your immune system has mounted a measurable IgG response to Candida. Common in healthy adults. Elevated levels may reflect heavier exposure, gut overgrowth, or active infection depending on clinical context. |
Because different labs use different testing methods to measure this antibody, comparing results across labs is unreliable. Always compare your results within the same lab and the same testing method over time.
The biggest source of confusion with this test is background positivity. Most healthy adults have been exposed to Candida, so a positive IgG result in isolation is not alarming. It reflects immune memory, not necessarily a current problem.
A single Candida IgG reading is a snapshot of your immune response at one moment. It tells you that your body has encountered Candida, but it says little about whether something is actively happening. Tracking your level over time is far more informative. A stable, mildly positive result over several tests is a very different story than a level that doubles between two draws.
If you are testing proactively and have no symptoms, get a baseline reading, then retest in 6 to 12 months to establish your personal range. If you are tracking a suspected issue, such as recurrent yeast-related symptoms or gut problems, retesting every 3 to 4 months can help you see whether interventions (dietary changes, probiotics, antifungal treatment) are shifting your immune response. Always retest at the same lab using the same testing method.
Because this is a marker without standardized clinical cutpoints for preventive use, building your own trend data is especially valuable. You will have your own baseline to compare against as the science matures and more population data become available.
If your result is negative, you likely have low Candida exposure or a normal, unremarkable immune history with this fungus. No further action is needed unless you have symptoms that prompted the test.
If your result is positive but you feel well and have no gut, skin, or vaginal symptoms, this likely reflects normal exposure. Consider it a baseline and retest in 6 to 12 months. If the level stays stable, it is probably just your immune memory at work.
If your result is positive and you have unexplained symptoms (chronic bloating, recurrent yeast infections, fatigue, brain fog, or worsening GI issues), the result gains more weight as part of a broader picture. Next steps would include a stool analysis to check for Candida overgrowth directly, a complete blood count to evaluate your white blood cell populations, and an inflammation marker like hs-CRP (high-sensitivity C-reactive protein) to see if your body is mounting a broader inflammatory response. A gastroenterologist or an infectious disease specialist can help interpret the pattern.
If your result is strongly positive and rising on repeat testing, especially with concurrent symptoms, this warrants a more thorough evaluation. In rare cases, deep-seated Candida infections can occur even outside the hospital, particularly in people with diabetes, chronic steroid use, or immune-suppressing conditions. A doctor specializing in infectious disease can order more targeted testing, including blood cultures and a beta-D-glucan test (a marker that detects fungal cell wall components in the blood), to rule out invasive disease.
Candida Albicans Ab IgG is best interpreted alongside these tests.